Grace Therapeutics Inc (GRCE)

$2.25 -0.08 (-3.43%)
Market Cap 36.36M
Revenue (ttm) 0.00
Net Income (ttm) -9.57M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 519,988
Avg Vol 898,898
Day's Range N/A - N/A
Shares Out 15.47M
Stochastic %K 53%
Beta 0.32
Analysts Strong Sell
Price Target $8.17

Company Profile

Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to improve neurological symptoms of Ataxia-Telangiectasia (A-T) and GTX-101, a topical bioadhesive film-forming polymer for the treatment of pain associated with postherpetic neuralgi...

Industry: Biotechnology
Sector: Healthcare
Phone: 609 322 1602
Address:
103 Carnegie Center, Suite 300, Princeton, United States
justice3423
justice3423 May. 13 at 5:59 PM
$GRCE wish this thing had a little bit of juice
0 · Reply
mimiwor
mimiwor May. 13 at 5:03 PM
$REPL glad i am still holding some shares.... $GRCE You are pathetic..
0 · Reply
mimiwor
mimiwor May. 12 at 1:04 PM
$GRCE There are so many pp looking at this board (maybe most) praying for an offering in this range...wish they wouldn't get the opportunity...
1 · Reply
mimiwor
mimiwor May. 12 at 11:03 AM
$GRCE just tired to post..... hard to pump here
1 · Reply
Shunbab
Shunbab May. 12 at 10:45 AM
$GRCE whats cooking??? 😋
0 · Reply
Charlie50
Charlie50 May. 12 at 8:23 AM
$GRCE I don't see you post anymore here. Are you bearish on GRCE now?
0 · Reply
deweyeggbert
deweyeggbert May. 9 at 3:27 AM
$GRCE buying any dips.
0 · Reply
TradeMadeNow
TradeMadeNow May. 8 at 5:24 PM
$GRCE Look at the weekly chart... Working back up
0 · Reply
shade00tree
shade00tree May. 8 at 3:15 PM
$GRCE I mean, you’re so smart and shit, you know?
0 · Reply
deweyeggbert
deweyeggbert May. 8 at 2:40 PM
$GRCE added calls.
1 · Reply
Latest News on GRCE
Largest borrow rate increases among liquid names

2026-05-12T14:42:22.000Z - 1 day ago

Largest borrow rate increases among liquid names

BBAI BILI KDK MSTU PS SERV SOUN

Grace Therapeutics price target lowered to $4 from $11 at Craig-Hallum

2026-04-24T13:31:53.000Z - 19 days ago

Grace Therapeutics price target lowered to $4 from $11 at Craig-Hallum

Grace Therapeutics price target lowered to $8 from $12 at TD Cowen

2026-04-24T12:03:06.000Z - 19 days ago

Grace Therapeutics price target lowered to $8 from $12 at TD Cowen

Grace Therapeutics down 48% after receipt of CRL from FDA for GTx-104

2026-04-23T17:55:47.000Z - 20 days ago

Grace Therapeutics down 48% after receipt of CRL from FDA for GTx-104

Grace Therapeutics, Inc trading resumes

2026-04-23T17:52:41.000Z - 20 days ago

Grace Therapeutics, Inc trading resumes

US FDA declines to approve Grace Therapeutics' drug for a type of stroke

Apr 23, 2026, 1:25 PM EDT - 20 days ago

US FDA declines to approve Grace Therapeutics' drug for a type of stroke

Grace Therapeutics issued Complete Response Letter from FDA

2026-04-23T17:21:26.000Z - 20 days ago

Grace Therapeutics issued Complete Response Letter from FDA

Grace Therapeutics Provides Regulatory Update on New Drug Application for GTx-104

Apr 23, 2026, 1:13 PM EDT - 20 days ago

Grace Therapeutics Provides Regulatory Update on New Drug Application for GTx-104

Grace Therapeutics, Inc trading halted, news pending

2026-04-23T16:30:22.000Z - 20 days ago

Grace Therapeutics, Inc trading halted, news pending

Grace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026

Apr 14, 2026, 8:00 AM EDT - 4 weeks ago

Grace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026

Grace Therapeutics to Present Data on the Unmet Medical Needs and Potential Benefits of GTx-104 in the Treatment of aSAH at Upcoming Medical Conferences

Mar 19, 2026, 8:00 AM EDT - 7 weeks ago

Grace Therapeutics to Present Data on the Unmet Medical Needs and Potential Benefits of GTx-104 in the Treatment of aSAH at Upcoming Medical Conferences

Grace Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Mar 4, 2026, 10:30 AM EST - 2 months ago

Grace Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Grace Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference

Feb 25, 2026, 8:00 AM EST - 2 months ago

Grace Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference

Grace Therapeutics reports Q3 EPS (14c) vs (36c) last year

2026-02-12T13:08:12.000Z - 3 months ago

Grace Therapeutics reports Q3 EPS (14c) vs (36c) last year

Grace Therapeutics Announces Third Quarter 2026 Financial Results, Provides Business Update

Feb 12, 2026, 8:00 AM EST - 3 months ago

Grace Therapeutics Announces Third Quarter 2026 Financial Results, Provides Business Update

Ten new option listings and two option delistings on January 22nd

2026-01-22T13:36:05.000Z - 3 months ago

Ten new option listings and two option delistings on January 22nd

AARD AVR BANX CLYM INR MENS NGEN

Grace Therapeutics to Participate in 16th Annual Craig-Hallum Alpha Select Conference

Nov 17, 2025, 8:00 AM EST - 6 months ago

Grace Therapeutics to Participate in 16th Annual Craig-Hallum Alpha Select Conference

Grace Therapeutics reports Q2 EPS (6c) vs (30c) last year

2025-11-13T13:10:34.000Z - 6 months ago

Grace Therapeutics reports Q2 EPS (6c) vs (30c) last year

Grace Therapeutics Announces Second Quarter 2026 Financial Results, Provides Business Update

Nov 13, 2025, 8:00 AM EST - 6 months ago

Grace Therapeutics Announces Second Quarter 2026 Financial Results, Provides Business Update

Grace Therapeutics Announces Abstract Accepted for Presentation at Society of Vascular and Interventional Neurology Annual Meeting

Nov 11, 2025, 8:30 AM EST - 6 months ago

Grace Therapeutics Announces Abstract Accepted for Presentation at Society of Vascular and Interventional Neurology Annual Meeting

Grace Therapeutics secures $4M through common warrant exercises

2025-10-23T12:15:45.000Z - 7 months ago

Grace Therapeutics secures $4M through common warrant exercises

Grace Therapeutics Secures Approximately $4.0 Million through Common Warrant Exercises Following Acceptance of New Drug Application for GTx-104 for formal FDA Review

Oct 23, 2025, 8:00 AM EDT - 7 months ago

Grace Therapeutics Secures Approximately $4.0 Million through Common Warrant Exercises Following Acceptance of New Drug Application for GTx-104 for formal FDA Review

Grace Therapeutics announces presentation of Phase 3 STRIVE-ON safety trial

2025-09-22T12:21:05.000Z - 8 months ago

Grace Therapeutics announces presentation of Phase 3 STRIVE-ON safety trial

Grace Therapeutics Pivotal Phase 3 STRIVE-ON Safety Trial Presented at 2025 Neurocritical Care Annual Meeting

Sep 22, 2025, 8:00 AM EDT - 8 months ago

Grace Therapeutics Pivotal Phase 3 STRIVE-ON Safety Trial Presented at 2025 Neurocritical Care Annual Meeting

Grace granted sixth U.S. patent covering I.V. dosing regimen for GTx-104

2025-09-18T12:41:21.000Z - 8 months ago

Grace granted sixth U.S. patent covering I.V. dosing regimen for GTx-104

Grace Therapeutics Granted Sixth U.S. Patent Covering I.V. Dosing Regimen for GTx-104

Sep 18, 2025, 8:30 AM EDT - 8 months ago

Grace Therapeutics Granted Sixth U.S. Patent Covering I.V. Dosing Regimen for GTx-104

Grace Therapeutics Transcript: Q3 Investor Summit Group Virtual Conference 2025

Sep 16, 2025, 3:30 PM EDT - 8 months ago

Grace Therapeutics Transcript: Q3 Investor Summit Group Virtual Conference 2025

Grace Therapeutics Announces Presentation at The H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 8:00 AM EDT - 8 months ago

Grace Therapeutics Announces Presentation at The H.C. Wainwright 27th Annual Global Investment Conference

Grace Therapeutics announces U.S. FDA accepted NDA for GTx-104 for review

2025-08-27T12:06:17.000Z - 9 months ago

Grace Therapeutics announces U.S. FDA accepted NDA for GTx-104 for review

Grace Therapeutics Announces U.S. Food and Drug Administration Acceptance for Review of New Drug Application for GTx-104

Aug 27, 2025, 8:00 AM EDT - 9 months ago

Grace Therapeutics Announces U.S. Food and Drug Administration Acceptance for Review of New Drug Application for GTx-104

Grace Therapeutics reports Q1 EPS (21c) vs (24c) last year

2025-08-12T12:10:54.000Z - 9 months ago

Grace Therapeutics reports Q1 EPS (21c) vs (24c) last year

Grace Therapeutics Announces First Quarter 2026 Financial Results, Provides Business Update

Aug 12, 2025, 8:00 AM EDT - 9 months ago

Grace Therapeutics Announces First Quarter 2026 Financial Results, Provides Business Update

Grace Therapeutics management to meet virtually with Craig-Hallum

2025-07-17T17:05:36.000Z - 10 months ago

Grace Therapeutics management to meet virtually with Craig-Hallum

Grace Therapeutics announces submission to U.S. FDA of NDA for GTx-104

2025-06-25T12:05:35.000Z - 11 months ago

Grace Therapeutics announces submission to U.S. FDA of NDA for GTx-104

Grace Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for GTx-104

Jun 25, 2025, 8:00 AM EDT - 11 months ago

Grace Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for GTx-104

Grace Therapeutics reports FY25 EPS (79c), consensus ($1.66)

2025-06-23T17:01:24.000Z - 11 months ago

Grace Therapeutics reports FY25 EPS (79c), consensus ($1.66)

Grace Therapeutics Announces 2025 Fiscal Year-End Results, Provides Business Update

Jun 23, 2025, 8:00 AM EDT - 11 months ago

Grace Therapeutics Announces 2025 Fiscal Year-End Results, Provides Business Update

Grace Therapeutics to Participate in the 2025 BIO International Conference

Jun 13, 2025, 8:00 AM EDT - 11 months ago

Grace Therapeutics to Participate in the 2025 BIO International Conference

Grace Therapeutics Announces Alignment with the FDA Supporting the Planned NDA Submission for GTx-104

Apr 9, 2025, 8:00 AM EDT - 1 year ago

Grace Therapeutics Announces Alignment with the FDA Supporting the Planned NDA Submission for GTx-104

Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors

Mar 11, 2025, 7:00 AM EDT - 1 year ago

Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors

MTNB

Grace Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 4, 2025, 2:30 PM EST - 1 year ago

Grace Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Grace Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference

Feb 25, 2025, 8:00 AM EST - 1 year ago

Grace Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference

Grace Therapeutics Announces Third Fiscal Quarter 2025 Financial Results, Provides Business Update

Feb 13, 2025, 8:00 AM EST - 1 year ago

Grace Therapeutics Announces Third Fiscal Quarter 2025 Financial Results, Provides Business Update

Grace Therapeutics Announces Private Placement Financing of up to $30 Million

Feb 10, 2025, 8:05 AM EST - 1 year ago

Grace Therapeutics Announces Private Placement Financing of up to $30 Million

Grace Therapeutics Announces Results From Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH

Feb 10, 2025, 8:01 AM EST - 1 year ago

Grace Therapeutics Announces Results From Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH

Grace Therapeutics to Participate in Upcoming Investor Events January 2025

Jan 7, 2025, 8:00 AM EST - 1 year ago

Grace Therapeutics to Participate in Upcoming Investor Events January 2025

Grace Therapeutics Transcript: KOL Event

Nov 20, 2024, 2:00 PM EST - 1 year ago

Grace Therapeutics Transcript: KOL Event

Acasti Announces Corporate Name Change to Grace Therapeutics, Inc.

Oct 25, 2024, 8:00 AM EDT - 1 year ago

Acasti Announces Corporate Name Change to Grace Therapeutics, Inc.

Acasti Announces Completion of Patient Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial of GTX-104

Sep 25, 2024, 7:30 AM EDT - 1 year ago

Acasti Announces Completion of Patient Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial of GTX-104

Grace Therapeutics Transcript: Life Sciences Investor Forum 2024

Sep 19, 2024, 12:30 PM EDT - 1 year ago

Grace Therapeutics Transcript: Life Sciences Investor Forum 2024

Grace Therapeutics Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 9, 2024, 7:00 AM EDT - 1 year ago

Grace Therapeutics Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Acasti to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Sep 5, 2024, 10:35 AM EDT - 1 year ago

Acasti to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Acasti Announces First Fiscal Quarter 2025 Financial Results, Provides Business Update

Aug 9, 2024, 8:00 AM EDT - 1 year ago

Acasti Announces First Fiscal Quarter 2025 Financial Results, Provides Business Update

Acasti Announces Achievement of 50% Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial

Jun 27, 2024, 4:05 PM EDT - 2 years ago

Acasti Announces Achievement of 50% Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial

Acasti Announces Year-End 2024 Financial Results, Provides Business Update

Jun 21, 2024, 8:00 AM EDT - 2 years ago

Acasti Announces Year-End 2024 Financial Results, Provides Business Update

Acasti Pharma to Attend BIO International Convention 2024

May 28, 2024, 4:05 PM EDT - 2 years ago

Acasti Pharma to Attend BIO International Convention 2024

Acasti Announces Third Fiscal Quarter 2024 Financial Results and Business Highlights

Feb 12, 2024, 8:00 AM EST - 2 years ago

Acasti Announces Third Fiscal Quarter 2024 Financial Results and Business Highlights

Acasti Announces Poster Detailing its GTX-104 STRIVE-ON Trial

Feb 1, 2024, 8:00 AM EST - 2 years ago

Acasti Announces Poster Detailing its GTX-104 STRIVE-ON Trial

Acasti to Participate in Upcoming San Francisco Investor Conferences in January 2024

Dec 13, 2023, 8:00 AM EST - 2 years ago

Acasti to Participate in Upcoming San Francisco Investor Conferences in January 2024

Acasti Announces Second Quarter 2024 Financial Results and Business Highlights

Nov 13, 2023, 8:00 AM EST - 2 years ago

Acasti Announces Second Quarter 2024 Financial Results and Business Highlights

Acasti Announces Dosing of First Patient in GTX-104 STRIVE-ON Trial

Oct 23, 2023, 8:00 AM EDT - 2 years ago

Acasti Announces Dosing of First Patient in GTX-104 STRIVE-ON Trial

Acasti Pharma to Host KOL Event on GTX-104: A Potential New Treatment Standard for Rare and Life-Threatening aneurysmal Subarachnoid Hemorrhage (aSAH)

Oct 4, 2023, 8:00 AM EDT - 2 years ago

Acasti Pharma to Host KOL Event on GTX-104: A Potential New Treatment Standard for Rare and Life-Threatening aneurysmal Subarachnoid Hemorrhage (aSAH)

Acasti Announces $7.5 Million Private Placement Equity Financing

Sep 26, 2023, 8:00 AM EDT - 2 years ago

Acasti Announces $7.5 Million Private Placement Equity Financing

Acasti to Participate in the H.C. Wainwright Global Investment Conference

Sep 6, 2023, 8:00 AM EDT - 2 years ago

Acasti to Participate in the H.C. Wainwright Global Investment Conference

Acasti Announces First Quarter 2024 Financial Results and Business Highlights

Aug 11, 2023, 7:00 AM EDT - 2 years ago

Acasti Announces First Quarter 2024 Financial Results and Business Highlights

Acasti to Present GTX-104 Pharmacokinetic Comparison Data at Neurocritical Care Annual Meeting

Aug 9, 2023, 4:05 PM EDT - 3 years ago

Acasti to Present GTX-104 Pharmacokinetic Comparison Data at Neurocritical Care Annual Meeting

Acasti Announces WuXi Clinical as CRO to Conduct STRIVE-ON Pivotal Phase 3 Safety Trial for GTX-104 in aSAH Patients

Jul 10, 2023, 9:00 AM EDT - 3 years ago

Acasti Announces WuXi Clinical as CRO to Conduct STRIVE-ON Pivotal Phase 3 Safety Trial for GTX-104 in aSAH Patients

Acasti Pharma Announces 1-for-6 Reverse Stock Split

Jul 7, 2023, 8:00 AM EDT - 3 years ago

Acasti Pharma Announces 1-for-6 Reverse Stock Split

Acasti Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol and Confirms Planned Initiation of STRIVE-ON in aSAH Patients in Calendar Q4 2023

Jul 5, 2023, 9:00 AM EDT - 3 years ago

Acasti Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol and Confirms Planned Initiation of STRIVE-ON in aSAH Patients in Calendar Q4 2023

Acasti Pharma Reports Fiscal Year 2023 Operational Results

Jun 23, 2023, 7:00 AM EDT - 3 years ago

Acasti Pharma Reports Fiscal Year 2023 Operational Results

Acasti Announces Appointment of New Scientific Advisory Board Members

Jun 22, 2023, 9:00 AM EDT - 3 years ago

Acasti Announces Appointment of New Scientific Advisory Board Members

Acasti to Participate in the Lytham Partners Spring 2023 Investor Conference

May 17, 2023, 9:00 AM EDT - 3 years ago

Acasti to Participate in the Lytham Partners Spring 2023 Investor Conference

Acasti Successfully Submits Pivotal GTX-104 Phase 3 Safety Study Protocol with FDA and Implements Strategic Realignment Plan That Extends Projected Cash Runway Through Calendar Q2 2025

May 8, 2023, 7:00 AM EDT - 3 years ago

Acasti Successfully Submits Pivotal GTX-104 Phase 3 Safety Study Protocol with FDA and Implements Strategic Realignment Plan That Extends Projected Cash Runway Through Calendar Q2 2025

Acasti to Proceed with Phase 3 Clinical Safety Study for GTX-104 Following FDA Feedback, and Upon Approval of the Full Study Protocol to be Submitted to the IND

Apr 4, 2023, 8:01 AM EDT - 3 years ago

Acasti to Proceed with Phase 3 Clinical Safety Study for GTX-104 Following FDA Feedback, and Upon Approval of the Full Study Protocol to be Submitted to the IND

justice3423
justice3423 May. 13 at 5:59 PM
$GRCE wish this thing had a little bit of juice
0 · Reply
mimiwor
mimiwor May. 13 at 5:03 PM
$REPL glad i am still holding some shares.... $GRCE You are pathetic..
0 · Reply
mimiwor
mimiwor May. 12 at 1:04 PM
$GRCE There are so many pp looking at this board (maybe most) praying for an offering in this range...wish they wouldn't get the opportunity...
1 · Reply
mimiwor
mimiwor May. 12 at 11:03 AM
$GRCE just tired to post..... hard to pump here
1 · Reply
Shunbab
Shunbab May. 12 at 10:45 AM
$GRCE whats cooking??? 😋
0 · Reply
Charlie50
Charlie50 May. 12 at 8:23 AM
$GRCE I don't see you post anymore here. Are you bearish on GRCE now?
0 · Reply
deweyeggbert
deweyeggbert May. 9 at 3:27 AM
$GRCE buying any dips.
0 · Reply
TradeMadeNow
TradeMadeNow May. 8 at 5:24 PM
$GRCE Look at the weekly chart... Working back up
0 · Reply
shade00tree
shade00tree May. 8 at 3:15 PM
$GRCE I mean, you’re so smart and shit, you know?
0 · Reply
deweyeggbert
deweyeggbert May. 8 at 2:40 PM
$GRCE added calls.
1 · Reply
Bulldog1776
Bulldog1776 May. 8 at 1:33 PM
$GRCE jackass
0 · Reply
Bulldog1776
Bulldog1776 May. 8 at 1:32 PM
$GRCE fuck you mother-fucker
0 · Reply
shade00tree
shade00tree May. 8 at 10:41 AM
$GRCE shocker they haven’t made you an offer yet for CEO.
0 · Reply
Bulldog1776
Bulldog1776 May. 8 at 1:59 AM
$GRCE they need to come out with details on the CRL that they got. They should then provide a path forward to help build confidence and bring the stock price up. It’s not that hard folks. Give a damn about your investors!
1 · Reply
zed_rickel
zed_rickel May. 7 at 3:07 AM
$GRCE definitely
0 · Reply
mimiwor
mimiwor May. 6 at 8:04 PM
$GRCE Stay tune here... Form-4 is coming...
0 · Reply
mimiwor
mimiwor May. 6 at 6:44 PM
$GRCE It was very nice to see you today..
0 · Reply
mimiwor
mimiwor May. 6 at 6:27 PM
$REPL Officailly double... still hold few k shares.... $GRCE Did you see a giant green candle? Market maker was giving you a sign.... do your DD. There is more to come...
0 · Reply
mimiwor
mimiwor May. 6 at 5:46 PM
$REPL moving my profit to $GRCE come join us.
0 · Reply
mimiwor
mimiwor May. 6 at 5:42 PM
$REPL lol. Just made double..... $GRCE she is next.
0 · Reply
zed_rickel
zed_rickel May. 6 at 5:37 PM
$GRCE where the heck did that volume come from
1 · Reply
mimiwor
mimiwor May. 6 at 5:21 PM
$GRCE lol
0 · Reply